ANI Pharmaceuticals: Is the current share price a reflection of long-term value after strong multi-year returns?

ANI Pharmaceuticals (ANIP) delivered a 35.2% return over the past year, with a value score of 3/6 on our framework of six valuation checks. The Discounted Cash Flow (DCF) analysis suggests an intrinsic discount of about 78.5%, indicating the stock is undervalued according to this method. However, the stock's current price and past returns may be influenced by ongoing product portfolio developments and regulatory updates in the specialty pharma space.